Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Point72

Steve Cohen's Point72 Buys $20M of Surging Biotech Stock That Recently Priced $125M Offering to Advance Myeloma Treatment

Cohen's Point72 purchased over 8 million shares of C4 Therapeutics within weeks of the company announcing phase 1 trial data of a drug to treat myeloma and raised $125 million to fund upcoming trials.

International Business Times UK

Cohen's Point72 Pours $14M in This Biotech Stock That Gained 250% in a Month, and Recently Raised $138M in Funding

Steve Cohen's Point72 Asset Management added Palisade Bio to the hedge fund's portfolio amid the company's announcement of positive phase 1 trial data and funding to advance phase 2 trials.

International Business Times UK

Steven Cohen Doubles The S&P 500 — And His Next Bet's All Gut

Steven Cohen's Point72 Asset Management just pulled off what most fund managers only dream of — doubling the SP 500's three-year return — and he's still not easing up. The billionaire investor's next move? A fresh swing into biotech, backing Palisade Bio Inc (NASDAQ:PALI) — a tiny, high-volatility stock working…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Here's Why Point72's Steve Cohen's Bought Millions Worth of Biotech Stocks Last Week

New York Mets owner and billionaire investor Steve Cohen purchased two biotech stocks last week, one being a new addition to Point 72's portfolio.

International Business Times UK

Steven Cohen's Biotech Bets Are Getting Bolder — And Smaller

Steven Cohen isn't afraid of volatility — and his latest moves show he's diving headfirst into small-cap biotech. The billionaire hedge fund manager's Point72 Asset Management has built new stakes in two clinical-stage companies, betting that their breakthroughs in genetic and antibody therapies could deliver outsized returns.

Benzinga

Steve Cohen's Point72 Goes Heavy on Tech and Pharma Stocks, Investing Over $330M in Two Trades

Point72 Asset Management recently purchased over 10 million shares of Confluent and Amylyx Pharma common stock, worth more than $334.17 million.

International Business Times UK

Here's Why Steve Cohen's Point72 Recently Shelled Out Over $100M for Two Biopharma Stocks

Billionaire investor Steve Cohen invested over $100 million in two biopharma stocks, one of which has rallied over 90% in the past one month.

International Business Times UK

Read news from The Economist, FT, and more,
with one subscription

Point72's Steve Cohen Adds $2B Worth of New Tech, Telco, and Healthcare Stocks in Q4

Billionaire investor Steven A. Cohen opened new stock positions, including Amazon, AT&T, Netflix, Salesforce, and UnitedHealth Group in Q4.

International Business Times UK

Billionaire hedge fund exec and Mets owner Steve Cohen says the key to success is to never stop working

The best traders are just like the best baseball players: “They can’t wait to work, even in the offseason.”

Fortune

Steve Cohen's Point72 to Raise $1 Billion for Launching AI-focused Hedge Fund

Steve Cohen recently revealed he is bullish on AI and believes it can significantly improve productivity in companies across industries.

International Business Times UK

Steve Cohen's Point72 Ups Stake in Boeing by Over 400% in Q1, Opens New Position in Broadcom

Boeing has trimmed delivery and production of its 737 Max fleet, while Broadcom's quarterly revenue jumped 34% YoY on high chip demand for AI data centres.

International Business Times UK

For Mets Owner Steve Cohen NYC Casino Ambitions Part Of A Diversification Strategy

For Mets Owner Steve Cohen, NYC Casino Ambitions Are Part Of A Diversification Strategy

Zenger

For Mets Owner Steve Cohen Has NYC Casino Ambitions Part Of A Diversification Strategy

For Mets Owner Steve Cohen, NYC Casino Ambitions Are Part Of A Diversification Strategy

Zenger

Stock Picks That Billionaires Love

Billionaire investors are scooping up beaten-down blue chips when they're on sale.

Kiplinger

Get all your
news in one place.

100’s of premium titles.
One news app.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.